The α7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome
- 1 October 2015
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 97 (4) , 363-377
Abstract
No abstract availableKeywords
Funding Information
- Commonwealth Health Research Board (#274-11-13)
- Office of the Dean of Eastern Virginia Medical School
- Families of Autistic Children in Tidewater (F.A.C.T.)
This publication has 56 references indexed in Scilit:
- Nicotinic ACh receptors as therapeutic targets in CNS disordersTrends in Pharmacological Sciences, 2015
- Targeting the α7 nicotinic acetylcholine receptor to prevent progressive dementia and improve cognition in adults with Down's syndromeProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2014
- Merging old and new perspectives on nicotinic acetylcholine receptorsBiochemical Pharmacology, 2014
- Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studiesBiochemical Pharmacology, 2013
- Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of SchizophreniaNeuropsychopharmacology, 2011
- Cholinergic Abnormalities in AutismClinical Neuropharmacology, 2010
- Mammalian Nicotinic Acetylcholine Receptors: From Structure to FunctionPhysiological Reviews, 2009
- Neuroplasticity of Neocortical Circuits in SchizophreniaNeuropsychopharmacology, 2007
- Cholinergic Activity in Autism: Abnormalities in the Cerebral Cortex and Basal ForebrainAmerican Journal of Psychiatry, 2001
- Minireview: Nicotinic Acetylcholine Receptors on Hippocampal Neurons: Distribution on the Neuronal Surface and Modulation of Receptor ActivityJournal of Receptors and Signal Transduction, 1997